DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Oral administration of prednisone to control refractory vertigo in Meniere's disease: a pilot study.

Author(s): Morales-Luckie E, Cornejo-Suarez A, Zaragoza-Contreras MA, Gonzalez-Perez O

Affiliation(s): Department of Otolaryngology, Hospital de Especialidades del Centro Medico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.

Publication date & source: 2005-09, Otol Neurotol., 26(5):1022-6.

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVE: To establish whether the oral administration of moderate doses of prednisone reduces refractory vertigo in Meniere's disease. STUDY DESIGN: Blinded, randomized, controlled trial. SETTING: Tertiary referral center. PATIENTS: Patients with Meniere's disease with limited vertigo control (Class C) and severe disability (Scale 3). INTERVENTIONS: Two groups (n = 8 per group) were treated orally with either diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h) (control group), or the same treatment plus prednisone (0.35 mg/kg) daily for 18 weeks (prednisone group). MAIN OUTCOME MEASURES: The variables evaluated were the frequency and duration of vertigo, tinnitus, aural fullness, and audiographic parameters. The clinical surveillance was performed for 12 months after prednisone withdrawal. RESULTS: The frequency and duration of vertigo episodes were reduced by 50% and 30%, respectively, by prednisone treatment. Prednisone-treated patients manifested a significant reduction in tinnitus. No changes were observed in aural fullness or hearing. No metabolic or infectious disorders were observed. CONCLUSION: Oral prednisone helps to control refractory vertigo in Meniere's disease. These preliminary data suggest that prednisone can be a good noninvasive antivertigo management regimen for these patients.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017